Focused ultrasound-enhanced carboplatin delivery improves radiotherapy response and survival in a preclinical glioblastoma model
Year: 2026
Type: preprint
Abstract: Rationale Glioblastoma is highly resistant to conventional therapies due to the limited penetration of chemotherapeutics across the blood-brain and blood-tumor barriers (BBB, BTB). Although platinum-based drugs show strong cytotoxic and radiosensitizing properties in several cancers, their inability to achieve therapeutic concentrations within the central nervous system (CNS) severely limits their efficacy in brain tumors. This study investigated whether focused ultrasound (FUS)-mediated BBB/BTB disruption combined with intravenous carboplatin and stereotactic radiotherapy could improve drug delivery, tumor control, and survival in a preclinical glioblastoma model. Methods F98 glioma-bearing rats were treated with a single dose of 15 Gy radiation therapy (RT), carboplatin only, carboplatin + RT, FUS + carboplatin or FUS + carboplatin + RT. FUS-mediated permeabilization was confirmed by magnetic resonance imaging (MRI), and platinum accumulation was quantified by inductively coupled plasma mass spectrometry and synchrotron X-ray fluorescence. Tumor progression and microenvironmental changes were monitored using multiparametric MRI (diffusion, perfusion, and vascular permeability), followed by voxel-wise clustering analysis and histopathological validation. Results The FUS + carboplatin + RT group demonstrated the strongest therapeutic benefit, compared to all other treatment groups, yielding up to a 122% increase in median survival relative to the untreated group. This treatment also reduced necrotic core expansion and induced a transient increase in tumor perfusion, suggesting improved vascular function. FUS enhanced carboplatin delivery to both the tumor and peritumoral brain, with platinum distribution closely correlating with MRI signal enhancement. Voxel-wise clustering of multiparametric MRI identified biologically distinct tumor regions that were subsequently validated by immunohistochemistry. Conclusion The combination of FUS-mediated carboplatin delivery and radiotherapy represents a safe, non-invasive strategy that enhances drug delivery and improves survival in an aggressive preclinical model of glioblastoma. By overcoming a major limitation of current therapies, this approach shows promising potential for clinical translation.
Institutions: Inserm, Grenoble Institute of Neurosciences, Synchrotron Radiation for Biomedicine, Université Grenoble Alpes, Centre National de la Recherche Scientifique, IRMaGe, Université d'Orléans, Laboratoire Interdisciplinaire pour l’Innovation et la Recherche en Santé d’Orléans, Centre Hospitalier Universitaire de Grenoble, Institut pour l'avancée des biosciences, Département de Pharmacochimie Moléculaire, Institut polytechnique de Grenoble, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, Systèmes Moléculaires et nanoMatériaux pour l'Énergie et la Santé
Language: English
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Open Access status: green
Funders: Infrastructures en Biologie Santé et Agronomie, Agence Nationale de la Recherche, European Synchrotron Radiation Facility, Institut National de la Santé et de la Recherche Médicale, Ligue Contre le Cancer, Institut National Du Cancer, Fédération pour la Recherche sur le Cerveau, Groupement des Entreprises Françaises dans la lutte contre le Cancer, LabEx PRIMES
OpenAlex ID: W7234800800
